TORONTO, Jan. 31 /CNW/ - DELISTING REVIEW - Ambrilia Biopharma Inc. (the "Company") - Further to TSX Bulletin #2009-1000 dated August 6,
2009, TSX was prevented from continuing its expedited delisting review
of the Company (Symbol: AMB) as a result of a stay of proceedings pursuant to the Initial Order
issued on July 31, 2009 by the Superior Court of Quebec under the
Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, As Amended.
TSX has determined to resume its expedited delisting review of the
Company. Trading in the Company's common shares will be suspended from
trading at the close of market on Tuesday February 1, 2011.
About TMX Group
TMX Group's key subsidiaries operate cash and derivative markets for
multiple asset classes including equities, fixed income and energy.
Toronto Stock Exchange, TSX Venture Exchange, Montreal Exchange,
Natural Gas Exchange, Boston Options Exchange (BOX), Shorcan, Equicom
and other TMX Group companies provide trading markets, clearing
facilities, data products and other services to the global financial
community. TMX Group is headquartered in Toronto with offices in
Montreal, Calgary and Vancouver. For more information about TMX Group,
visit our website at www.tmx.com.
SOURCE TMX GROUP INC.
For further information:
Corporate Communications, TMX Group Inc., Toll Free 1-888-873-8392, email@example.com